NewAmsterdam Pharma Company N.V.

EDGAR

Market value

$2.39B

119,929,998 shares as of 2026-11-02, at $19.94 a share (NAMS, IEX close on 2026-11-12) Primary-source evidence

Annual consolidated revenue for 2025: about USD 22.5M, using the latest filing vintage with reviewed corrections applied. Corrected values apply reviewed corrections and remain separate from issuer reports. The previous period, 2024, was about USD 45.56M.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
1 transactions, 10,000 shares
Sum of shares × price per share: 226,500
Open-market sales (code S)
43 transactions, 1,970,479 shares
Sum of shares × price per share: 63,253,726.84 1 without a price are not valued.

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-09-30 Kastelein Johannes Jacob Pieter M 50,246 —
  • 2026-09-30 Kastelein Johannes Jacob Pieter S 50,246 25.03
  • 2026-09-30 Kastelein Johannes Jacob Pieter M 50,246 0
  • 2026-09-14 Davidson Michael H. P 10,000 22.65
  • 2026-09-04 Smither John W S 1,600 25.32

5% holders (Schedule 13D and 13G)

  • RA Capital Management, L.P. 9.9% SCHEDULE 13G/A 09/30/2026
  • Peter Kolchinsky 9.9% SCHEDULE 13G/A 09/30/2026
  • Rajeev Shah 9.9% SCHEDULE 13G/A 09/30/2026

Institutional holders (Form 13F)

  • Frazier Life Sciences Management, L.P. 19,489,235 SH
  • Capital World Investors 12,881,484 SH
  • FMR LLC 12,116,744 SH
  • RA CAPITAL MANAGEMENT, L.P. 9,883,524 SH
  • Janus Henderson Group Ltd. 8,972,293 SH

Trades by members of Congress

See all insider transactions

Latest quarter

Revenue

19.2 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating margin

-230.58%

2026 Q3 · %

Exact inputs and evidence
  • Operating Income: -44188000 USD Source
  • Revenue: 19164000 USD Source

Operating cash flow

-39.8 million USD

2026 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: -109591000 USD Source
  • Operating Cash Flow: -69818000 USD Source
Cash and cash equivalents
423 million USD Source
Exact value

423129000 USD

Long-term debt including current maturities
Not available
Shares outstanding
120 million shares Source
Exact value

119819484 shares

Reported share-count change

5.87% · 6.65 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 113172684 shares · 2025-09-30· Source
  • 119819484 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

25.9 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Revenue: 22503000 USD · 2025-01-01 – 2025-12-31 Source
  • Revenue: 22471000 USD · 2025-01-01 – 2025-09-30 Source
  • Revenue: 3040000 USD · 2026-01-01 – 2026-03-31 Source
  • Revenue: 3701000 USD · 2026-04-01 – 2026-06-30 Source
  • Revenue: 19164000 USD · 2026-07-01 – 2026-09-30 Source

Net income

-205 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Net income: -203819000 USD · 2025-01-01 – 2025-12-31 Source
  • Net income: -128896000 USD · 2025-01-01 – 2025-09-30 Source
  • Net income: -48441000 USD · 2026-01-01 – 2026-03-31 Source
  • Net income: -64135000 USD · 2026-04-01 – 2026-06-30 Source
  • Net income: -17389000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

-150 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: -147783000 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -106908000 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -30604000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -69818000 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -30604000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -109591000 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -69818000 USD · 2026-01-01 – 2026-06-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-04.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • Revenue: 4 of 11 periods available· newest 2025-12-31
  • Operating income: 5 of 11 periods available· newest 2025-12-31
  • Net income: 5 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 5 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 3 of 11 periods available· newest 2022-12-31
  • Total assets: 4 of 11 periods available· newest 2025-12-31
  • Total liabilities: 4 of 11 periods available· newest 2025-12-31
  • Current assets: 4 of 11 periods available· newest 2025-12-31
  • Current liabilities: 4 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Revenue

    -50.6%

    Prior period

    USD 45.56 million

    –

    Current period

    USD 22.5 million

    –

    Exact inputs and evidence

    22503000 − 45563000 = -23060000 USD

    45563000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    22503000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Net income

    +USD 37.78 million

    Prior period

    −USD 241.6 million

    –

    Current period

    −USD 203.82 million

    –

    Exact inputs and evidence

    -203819000 − -241598000 = 37779000 USD

    -241598000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -203819000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +USD 10.78 million

    Prior period

    −USD 158.56 million

    –

    Current period

    −USD 147.78 million

    –

    Exact inputs and evidence

    -147783000 − -158564000 = 10781000 USD

    -158564000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -147783000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

  • Revenue USD 22.5 million 100% of revenue
  • Operating costs Derived USD 248.19 million 1,103% of revenue
  • Operating income −USD 225.68 million −1,003% of revenue
  • Tax, interest and other Derived −USD 21.86 million −97% of revenue
  • Net income −USD 203.82 million −906% of revenue

Cash

  • Operating cash flow −USD 147.78 million −657% of revenue
  • Capital expenditure Unavailable An input is unavailable.
  • Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2022 Operating loss: operating costs were 103% of revenue.
  • 2023 Operating loss: operating costs were 1,399% of revenue.
  • 2024 Operating loss: operating costs were 487% of revenue.
  • 2025 Operating loss: operating costs were 1,103% of revenue.
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2022 2022-01-01 – 2022-12-31102694000 106251000 Derived -3557000 19077000 Derived -22634000 Unavailable
Source
2023 2023-01-01 – 2023-12-3114090000 197057000 Derived -182967000 -6030000 Derived -176937000 Unavailable
Source
2024 2024-01-01 – 2024-12-3145563000 221852000 Derived -176289000 65309000 Derived -241598000 Unavailable
Source
2025 2025-01-01 – 2025-12-3122503000 248186000 Derived -225683000 -21864000 Derived -203819000 Unavailable
Source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 22.5M 2025
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.110.9M83.2M55.5M27.7M0.02022202320242025
Values and sources
Revenue values and source evidence
PeriodSeriesValue(USD)Source evidence
2022Revenue102694000
2023Revenue14090000
2024Revenue45563000
2025Revenue22503000

Revenue growth

Change in revenue from the same financial period one year earlier.

-50.6% 2025
Revenue growth historyChange in revenue from the same financial period one year earlier. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.248%158%69%-21%-111%2022202320242025
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2022Year over yearNo prior comparable period
2023Year over year-86.3%
2024Year over year223.4%
2025Year over year-50.6%

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,002.9% 2025
Net margin -905.7% 2025
Profit margins historyOperating income, net income and free cash flow as a share of revenue. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.104%-273%-649%-1,026%-1,402%2022202320242025
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2022Operating margin-3.5%
2023Operating margin-1,298.6%
2024Operating margin-386.9%
2025Operating margin-1,002.9%
2022Net margin-22%
2023Net margin-1,255.8%
2024Net margin-530.3%
2025Net margin-905.7%
2022Free cash flow marginNot reported
2023Free cash flow marginNot reported
2024Free cash flow marginNot reported
2025Free cash flow marginNot reported

Operating cash flow

Cash generated by the company’s normal business operations.

USD -147.8M 2025
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.24.2M-24.9M-73.9M-123.0M-172.1M2022202320242025
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2022Operating cash flow10665000
2023Operating cash flow-141218000
2024Operating cash flow-158564000
2025Operating cash flow-147783000

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2022Free cash flowUnavailable
2023Free cash flowUnavailable
2024Free cash flowUnavailable
2025Free cash flowUnavailable

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

11.2% 2025
Liabilities to assets historyTotal liabilities as a share of total assets. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.18.3%13.7%9.1%4.6%0.0%2022202320242025
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2022Liabilities / assets10.1%
2023Liabilities / assets16.9%
2024Liabilities / assets12.4%
2025Liabilities / assets11.2%

Current assets to current liabilities

Current assets divided by current liabilities.

7.88× 2025
Current assets to current liabilities historyCurrent assets divided by current liabilities. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.14.32×10.74×7.16×3.58×0.00×2022202320242025
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2022Current assets / current liabilities13.26×
2023Current assets / current liabilities6.95×
2024Current assets / current liabilities8.08×
2025Current assets / current liabilities7.88×

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2021 2021-01-01 – 2021-12-31
−USD 41.79 million
Exact value

Exact value: -41785000 USD

2021-01-01 – 2021-12-31: -41785000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 29.51 million
Exact value

Exact value: -29512000 USD

2021-01-01 – 2021-12-31: -29512000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2022 2022-01-01 – 2022-12-31
−USD 22.63 million
Exact value

Exact value: -22634000 USD

2022-01-01 – 2022-12-31: -22634000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 10.67 million
Exact value

Exact value: 10665000 USD

2022-01-01 – 2022-12-31: 10665000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2023 2023-01-01 – 2023-12-31
−USD 176.94 million
Exact value

Exact value: -176937000 USD

2023-01-01 – 2023-12-31: -176937000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 141.22 million
Exact value

Exact value: -141218000 USD

2023-01-01 – 2023-12-31: -141218000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2024 2024-01-01 – 2024-12-31
−USD 241.6 million
Exact value

Exact value: -241598000 USD

2024-01-01 – 2024-12-31: -241598000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 158.56 million
Exact value

Exact value: -158564000 USD

2024-01-01 – 2024-12-31: -158564000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2025 2025-01-01 – 2025-12-31
−USD 203.82 million
Exact value

Exact value: -203819000 USD

2025-01-01 – 2025-12-31: -203819000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 147.78 million
Exact value

Exact value: -147783000 USD

2025-01-01 – 2025-12-31: -147783000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

58 filings · 994 latest values · 994 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001936258, 1936258, NAMS, NAMSW, edgar:1936258

Also known as NewAmsterdam Pharma Co B.V., NewAmsterdam Pharma Co N.V., NewAmsterdam Pharma Company N.V.